Literature DB >> 10155620

Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation.

J Rovira1, F Antoñanzas.   

Abstract

Mesh：

Year:  1995        PMID： 10155620     DOI： 10.2165/00019053-199508030-00007

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  17 in total

1.  A reappraisal of economic evaluation of pharmaceuticals. Science or marketing?

Authors:  M F Drummond
Journal:  Pharmacoeconomics       Date:  1998-07       Impact factor: 4.981

2.  Reporting format for economic evaluation. Part I: Application to the Dutch healthcare system.

Authors:  M J Nuijten; M J Brorens; Y A Hekster; A van der Kuy; J H Lockefeer; P A de Smet; G Bonsel; M H Pronk
Journal:  Pharmacoeconomics       Date:  1998-08       Impact factor: 4.981

3.  Standardisation of costs: the Dutch Manual for Costing in economic evaluations.

Authors:  Jan B Oostenbrink; Marc A Koopmanschap; Frans F H Rutten
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

4.  Providing systematic guidance in pharmacoeconomic guidelines for analysing costs.

Authors:  Philip Jacobs; Arto Ohinmaa; Bruce Brady
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Methods of economic evaluation for the German Statutory Healthcare System.

Authors:  Hengjin Dong
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

6.  Methodological reviews of economic evaluations in health care: what do they target?

Authors:  Maria-Florencia Hutter; Roberto Rodríguez-Ibeas; Fernando Antonanzas
Journal:  Eur J Health Econ       Date:  2013-08-24

7.  Prednicarbate versus fluocortin for inflammatory dermatoses. A cost-effectiveness study.

Authors:  A de Tiedra; J Mercadal; R Lozano
Journal:  Pharmacoeconomics       Date:  1997-08       Impact factor: 4.981

8.  The impact of a revised EQ-5D population scoring on preference-based utility scores in an inflammatory arthritis cohort.

Authors:  Roisin Adams; Benjamin M Craig; Cathal D Walsh; Douglas J Veale; Barry Bresnihan; Oliver FitzGerald; Michael Barry
Journal:  Value Health       Date:  2011-07-08       Impact factor: 5.725

9.  The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective.

Authors:  F Borgström; A Carlsson; H Sintonen; S Boonen; P Haentjens; R Burge; O Johnell; B Jönsson; J A Kanis
Journal:  Osteoporos Int       Date:  2006-03-29       Impact factor: 4.507

10.  Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.

Authors:  J M Gil; C Rubio-Terrés; A Del Castillo; P González; F Canorea
Journal:  Clin Transl Oncol       Date:  2006-05       Impact factor: 3.405
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.